Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 14/20 | 0.46 |
| ▸ | GAA | P10253 | 14/20 | 0.46 |
| ▸ | SI | P14410 | 14/20 | 0.46 |
| ▸ | MGAM2 | Q2M2H8 | 14/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | CBFB | Q13951 | 1/20 | 0.44 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.44 |
| ▸ | ATP4A | P20648 | 1/20 | 0.43 |
| ▸ | ATP4B | P51164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13908155 | 0.85 | MGAM (0.48) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL4359045 | 0.82 | MGAM (0.51) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL6755343 | 0.81 | CBFB (0.44) | GAAALDH1A1CBFBCACNA1H | |
| SCHEMBL30518181 | 0.81 | DDAH1 (0.55) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL4919548 | 0.81 | DDAH1 (0.55) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL4062820 | 0.79 | MGAM (0.51) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL7409334 | 0.79 | MGAM (0.49) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL4346855 | 0.79 | MGAM (0.51) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL19104695 | 0.78 | PARP1 (0.61) | — | |
| Hydrochloric Acid SCHEMBL23497514 | 0.78 | MGAM (0.47) | MGAMGAASIMGAM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0428260-B1 | Metal surface treatment agents | SANWA LAB LTD (JP) | 2000-01-05 | — | — | EP | claimed |
| EP-0562187-B1 | Process for production of copper through-hole printed wiring boards | SANWA LAB LTD (JP) | 1996-01-10 | — | — | EP | claimed |
| US-5275694-A | Printed circuits with copper through holes, negative patterns, photoresists, lamination, dipping and etching | SANWA LABORATORY LTD. (JP) | 1994-01-04 | — | — | US | claimed |
| EP-0562187-A1 | Process for production of copper through-hole printed wiring boards | SANWA LABORATORY LTD. (JP) | 1993-09-29 | — | — | EP | claimed |
| EP-0428260-A2 | Metal surface treatment agents | SANWA LABORATORY LTD. (JP) | 1991-05-22 | — | — | EP | claimed |
| EP-3675858-B1 | IMIDAZO[1,5-A]PYRAZINE COMPOUNDS AND COMPOSITIONS FOR IRE1 INHIBITION | OPTIKIRA LLC (US) | 2023-04-26 | — | — | EP | disclosed |
| US-20200354367-A1 | COMPOUNDS AND COMPOSITIONS FOR IRE1 INHIBITION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-11-12 | — | — | US | disclosed |
| US-6712262-B2 | BENZIMIDAZOLE AND IODINE COMPOUNDS | TAMURAKAKEN CORPORATION (JP) | 2004-03-30 | — | — | US | disclosed |
| US-20030141351-A1 | Water-soluble preflux, printed circuit board, and process for treating the surface of a metal in a printed circuit board | TAMURA CORPORATION (JP) | 2003-07-31 | — | — | US | disclosed |
| EP-0428260-B1 | Metal surface treatment agents | SANWA LAB LTD (JP) | 2000-01-05 | — | — | EP | disclosed |
| EP-0562187-B1 | Process for production of copper through-hole printed wiring boards | SANWA LAB LTD (JP) | 1996-01-10 | — | — | EP | disclosed |
| US-5275694-A | Printed circuits with copper through holes, negative patterns, photoresists, lamination, dipping and etching | SANWA LABORATORY LTD. (JP) | 1994-01-04 | — | — | US | disclosed |
| EP-0562187-A1 | Process for production of copper through-hole printed wiring boards | SANWA LABORATORY LTD. (JP) | 1993-09-29 | — | — | EP | disclosed |
| EP-0428260-A2 | Metal surface treatment agents | SANWA LABORATORY LTD. (JP) | 1991-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200354367-A1 | COMPOUNDS AND COMPOSITIONS FOR IRE1 INHIBITION | XBP1, RNASE1, ERN1 | MGAM 1407/4885GAA 548/4885SI 3862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.